Study Phase 3

A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

Trial Information

Generic NameGuselkumabProduct NameTREMFYA®Therapeutic AreaSkin and Connective Tissue DiseasesEnrollment872% Female35%% White85.8%
Product ClassAntipsoriaticsSponsor Protocol NumberCNTO1959PSO3003Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)43.1

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.